دورية أكاديمية
أعرض في EDS

Identifying stage-associated hub genes in bladder cancer via weighted gene co-expression network and robust rank aggregation analyses.

التفاصيل البيبلوغرافية
العنوان: Identifying stage-associated hub genes in bladder cancer via weighted gene co-expression network and robust rank aggregation analyses.
المؤلفون: Feng F; Department of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, Foshan, China., Zhong YX, Huang JH, Lin FX, Zhao PP, Mai Y, Wei W, Zhu HC, Xu ZP
المصدر: Medicine [Medicine (Baltimore)] 2022 Dec 23; Vol. 101 (51), pp. e32318.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Urinary Bladder Neoplasms*/genetics , Urinary Bladder Neoplasms*/pathology , Carcinoma, Transitional Cell*, Humans ; Gene Expression Profiling/methods ; Biomarkers, Tumor/genetics ; Gene Regulatory Networks
مستخلص: Background: Bladder cancer (BC) is among the most frequent cancers globally. Although substantial efforts have been put to understand its pathogenesis, its underlying molecular mechanisms have not been fully elucidated.
Methods: The robust rank aggregation approach was adopted to integrate 4 eligible bladder urothelial carcinoma microarray datasets from the Gene Expression Omnibus. Differentially expressed gene sets were identified between tumor samples and equivalent healthy samples. We constructed gene co-expression networks using weighted gene co-expression network to explore the alleged relationship between BC clinical characteristics and gene sets, as well as to identify hub genes. We also incorporated the weighted gene co-expression network and robust rank aggregation to screen differentially expressed genes.
Results: CDH11, COL6A3, EDNRA, and SERPINF1 were selected from the key module and validated. Based on the results, significant downregulation of the hub genes occurred during the early stages of BC. Moreover, receiver operating characteristics curves and Kaplan-Meier plots showed that the genes exhibited favorable diagnostic and prognostic value for BC. Based on gene set enrichment analysis for single hub gene, all the genes were closely linked to BC cell proliferation.
Conclusions: These results offer unique insight into the pathogenesis of BC and recognize CDH11, COL6A3, EDNRA, and SERPINF1 as potential biomarkers with diagnostic and prognostic roles in BC.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Pathol Res Pract. 2022 Nov;239:154141. (PMID: 36228347)
Onco Targets Ther. 2021 Jul 16;14:4211-4222. (PMID: 34295163)
Front Genet. 2015 May 13;6:174. (PMID: 26029240)
Oncol Lett. 2015 Aug;10(2):647-652. (PMID: 26622548)
J Neuromuscul Dis. 2021;8(4):633-645. (PMID: 33749658)
Aging (Albany NY). 2022 Nov 17;14(22):9037-9055. (PMID: 36399105)
Mol Genet Genomics. 2022 Jul;297(4):947-963. (PMID: 35532795)
BMC Bioinformatics. 2008 Dec 29;9:559. (PMID: 19114008)
Cancer Sci. 2019 Jan;110(1):408-419. (PMID: 30382619)
Medicine (Baltimore). 2022 Dec 23;101(51):e32318. (PMID: 36595851)
Diagnostics (Basel). 2022 Jun 30;12(7):. (PMID: 35885510)
Respir Res. 2019 Jul 8;20(1):143. (PMID: 31286980)
Cells Tissues Organs. 2023;212(4):293-303. (PMID: 35662129)
Int J Nanomedicine. 2015 Jan 20;10:791-800. (PMID: 25653521)
Front Oncol. 2022 Sep 28;12:790096. (PMID: 36249004)
Histol Histopathol. 2008 Sep;23(9):1069-76. (PMID: 18581278)
Anticancer Res. 2020 May;40(5):2715-2724. (PMID: 32366417)
Expert Rev Anticancer Ther. 2022 Mar;22(3):323-330. (PMID: 34836489)
Cancer Res. 2017 Nov 1;77(21):e108-e110. (PMID: 29092952)
J Epidemiol. 2023 Nov 5;33(11):582-588. (PMID: 36310059)
Nature. 2014 Jan 16;505(7483):344-52. (PMID: 24429633)
Biochim Biophys Acta Gene Regul Mech. 2020 Jun;1863(6):194417. (PMID: 31493559)
Biochem Biophys Res Commun. 2016 Sep 23;478(3):1106-10. (PMID: 27530920)
Immunol Lett. 2022 Aug;248:31-36. (PMID: 35667453)
Cancer Immunol Res. 2022 Aug 3;10(8):1013-1027. (PMID: 35679518)
Cancer Res. 2022 Apr 15;82(8):1560-1574. (PMID: 35149589)
J Cancer. 2021 Jan 1;12(4):1190-1199. (PMID: 33442417)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2209563119. (PMID: 36256815)
Cancer Res. 2020 Apr 15;80(8):1707-1719. (PMID: 32060149)
Bioinformatics. 2012 Feb 15;28(4):573-80. (PMID: 22247279)
Bioinformatics. 2013 Mar 1;29(5):661-3. (PMID: 23325622)
Sci Rep. 2016 Aug 31;6:32427. (PMID: 27576898)
J Cancer. 2020 Apr 14;11(14):4173-4180. (PMID: 32368300)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Oncol Lett. 2018 Feb;15(2):1417-1422. (PMID: 29399188)
Biosensors (Basel). 2022 Sep 27;12(10):. (PMID: 36290934)
Signal Transduct Target Ther. 2020 Jul 10;5(1):124. (PMID: 32651356)
Immunogenetics. 2021 Jun;73(3):207-226. (PMID: 33665735)
BMC Cancer. 2019 May 22;19(1):484. (PMID: 31117965)
Cancer Cell. 2020 Aug 10;38(2):247-262.e11. (PMID: 32589943)
Expert Rev Mol Diagn. 2019 Jul;19(7):579-590. (PMID: 31215265)
Front Oncol. 2022 Oct 10;12:1018285. (PMID: 36300085)
Wiley Interdiscip Rev RNA. 2018 May;9(3):e1471. (PMID: 29516680)
Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H812-26. (PMID: 26163443)
Gene. 2018 Nov 30;677:189-197. (PMID: 30025927)
Int J Mol Sci. 2022 Oct 15;23(20):. (PMID: 36293209)
Mol Cancer. 2010 Jan 08;9:3. (PMID: 20059769)
Ann Oncol. 2006 May;17 Suppl 5:v129-32. (PMID: 16807440)
Cancer Manag Res. 2019 Mar 28;11:2517-2529. (PMID: 31114321)
Cell Cycle. 2018;17(4):486-491. (PMID: 29251172)
Stat Appl Genet Mol Biol. 2005;4:Article17. (PMID: 16646834)
J Urol. 2009 Aug;182(2):741-8. (PMID: 19539325)
Int J Oncol. 2022 Dec;61(6):. (PMID: 36263625)
Int J Cancer. 2013 Sep 1;133(5):1135-42. (PMID: 23436614)
Pathol Oncol Res. 2020 Apr;26(2):1063-1072. (PMID: 31011911)
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20230103 Date Completed: 20230105 Latest Revision: 20240910
رمز التحديث: 20240910
مُعرف محوري في PubMed: PMC9794320
DOI: 10.1097/MD.0000000000032318
PMID: 36595851
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000032318